Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Yumanity Therapeutics (Nasdaq: YMTX), a biopharmaceutical company focused on neurodegenerative diseases, will present at the H.C. Wainwright Global Life Sciences Conference. CEO Richard Peters, M.D., Ph.D., will deliver the presentation, available on-demand starting March 9 at 7:00 a.m. EST on the conference portal and the company website. Yumanity is currently developing YTX-7739, a therapy in Phase 1 trials for Parkinson's disease, and has a diverse pipeline addressing various neurodegenerative conditions. More details can be found at yumanity.com.

BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference.

The presentation will be available on-demand via the conference portal and through the Company's website at yumanity.com/events beginning March 9, starting at 7:00am EST.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease.   For more information, please visit www.yumanity.com.

Contacts
Investors:
Burns McClellan, Inc.
John Grimaldi
jgrimaldi@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006

FAQ

What is the date of the Yumanity Therapeutics presentation at the conference?

The presentation at the H.C. Wainwright Global Life Sciences Conference by Yumanity Therapeutics will be available on-demand starting March 9, 2021, at 7:00 a.m. EST.

Who will present for Yumanity Therapeutics at the conference?

Richard Peters, M.D., Ph.D., the President and CEO, will present for Yumanity Therapeutics at the conference.

What is Yumanity Therapeutics' main product candidate?

Yumanity Therapeutics' main product candidate is YTX-7739, currently in Phase 1 clinical development for Parkinson's disease.

What diseases is Yumanity Therapeutics targeting?

Yumanity Therapeutics is focused on developing therapies for Parkinson's disease, Lewy body dementia, multi-system atrophy, ALS, frontotemporal lobar dementia, and Alzheimer's disease.

Where can I watch the Yumanity Therapeutics presentation?

You can watch the Yumanity Therapeutics presentation on-demand at the conference portal and through their website at yumanity.com/events.